Grufity logoGrufity logo

Verona Pharma PLC Stock Research

VRNA

22.90USD+0.20(+0.88%)Delayedas of 23 Jan 2023, 10:12 am

Market Summary

USD22.90+0.20
Delayedas of 23 Jan 2023, 10:12 am
0.88%

VRNA Alerts

VRNA Stock Price

VRNA RSI Chart

VRNA Valuation

Market Cap

13.9B

Price/Earnings (Trailing)

-169.93

Price/Sales (Trailing)

126.66

EV/EBITDA

-169.15

Price/Free Cashflow

-199.44

VRNA Price/Sales (Trailing)

VRNA Profitability

EBT Margin

-136.94%

Return on Equity

-34.32%

Return on Assets

-29.65%

Free Cashflow Yield

-0.5%

VRNA Fundamentals

VRNA Revenue

Revenue (TTM)

40.0M

Revenue Y/Y

378.26%

Revenue Q/Q

100%

VRNA Earnings

Earnings (TTM)

-81.5M

Earnings Y/Y

19.49%

Earnings Q/Q

28.47%

Price Action

52 Week Range

3.4126.44
(Low)(High)

Last 7 days

-5.1%

Last 30 days

-2.2%

Last 90 days

115.8%

Trailing 12 Months

242.9%

VRNA Financial Health

Current Ratio

8.04

VRNA Investor Care

Shares Dilution (1Y)

26.08%

Diluted EPS (TTM)

-0.17

Financials for Verona Pharma

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
RevenueNaN%nullnull40,000,00030,069,00020,138,000
Gross Profit-160,000,000----
Operating Expenses-7.0%107,482,000115,522,000113,313,000112,547,000-
  S&GA Expenses-7.7%29,606,00032,065,00033,907,00039,604,000-
  R&D Expenses-6.7%77,876,00083,457,00079,406,00072,943,000-
EBITDA7.5%-53,778,000.00-58,153,000.00-54,618,000.00--
EBITDA Margin7.5%-1.34-1.45---
Earnings Before Taxes7.4%-54,776,000.00-59,132,000.00-55,587,000.00-56,864,000.00-
EBT Margin7.4%-1.37-1.48---
Interest Expenses1.8%346,000340,000340,000290,000-
Net Income7.3%-54,814,000.00-59,116,000.00-55,569,000.00-57,132,000.00-
Net Income Margin7.3%-1.37-1.48---
Free Cahsflow2.3%-28,551,000.00-29,227,000.00-33,266,000.00--
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets77.5%275155169187202
  Current Assets86.4%258139153170184
    Cash Equivalents107.8%232112133148167
  Net PPE-11.0%00000
  Goodwill-0.2%11111
Liabilities-15.0%3744433933
  Current Liabilities-17.3%3239383328
    LT Debt, Non Current1.1%55555
Shareholder's Equity114.2%237111126148168
  Retained Earnings-5.1%-322.44-306.65-288.74-263.72-240.29
  Additional Paid-In Capital34.6%526391388385382
Shares Outstanding24.1%602485483480478
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-143.4%-69,447.00-28,527.00-29,215.00-33,254.00-34,726.00
  Share Based Compensation-13.3%13,80415,92620,32325,42534,112
Cashflow From Investing26.8%-30.00-41.00-12.00-12.00-20.00
Cashflow From Financing3422.1%137,303-4,133.00-6,843.00-6,117.00-1,266.00

Risks for VRNA

What is the probability of a big loss on VRNA?

100%


Probability that Verona Pharma stock will be more than 20% underwater in next one year

100%


Probability that Verona Pharma stock will be more than 30% underwater in next one year.

87.7%


Probability that Verona Pharma stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VRNA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Verona Pharma was unfortunately bought at previous high price.

Drawdowns

Returns for VRNA

Cumulative Returns on VRNA

12.1%


5-Year Cumulative Returns

52.4%


3-Year Cumulative Returns

What are the long-term rolling returns for VRNA?

FIve years rolling returns for Verona Pharma.

Annualized Returns

Which funds bought or sold VRNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-01-19
Stratos Wealth Partners, LTD.
new
-
479,747
479,747
0.01%
2023-01-13
JANUS HENDERSON GROUP PLC
new
-
6,138,000
6,138,000
-%
2022-11-16
GLENMEDE TRUST CO NA
new
-
308,000
308,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
sold off
-
-
-
-%
2022-11-15
STATE STREET CORP
new
-
4,234,000
4,234,000
-%
2022-11-14
Octagon Capital Advisors LP
new
-
13,540,000
13,540,000
2.34%
2022-11-14
TWO SIGMA ADVISERS, LP
new
-
1,568,000
1,568,000
-%
2022-11-14
BREWIN DOLPHIN LTD
unchanged
-
-1,000
3,000
-%
2022-11-14
SPHERA FUNDS MANAGEMENT LTD.
new
-
1,226,000
1,226,000
0.17%
2022-11-14
NEA Management Company, LLC
added
9.32
35,671,000
57,076,000
2.85%

1–10 of 44

Latest Funds Activity

Are funds buying VRNA calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own VRNA
No. of Funds

Verona Pharma News

Seeking Alpha

Healthcare Outlook 2023.

Seeking Alpha,
14 minutes ago

Marketscreener.com

European Equities Begin Week With Sharp Rise.

Marketscreener.com,
13 days ago

Marketscreener.com

InvestorsObserver

Schedule 13G FIlings of Verona Pharma

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Dec 27, 2022
orbimed advisors llc
5.6%
4,260,691
SC 13D/A
Sep 07, 2022
growth equity opportunities fund iv, llc
7.9%
46,447,651
SC 13D/A
Feb 14, 2022
ra capital management, l.p.
9.99%
48,778,172
SC 13G/A
Feb 11, 2022
vivo ventures vi, llc
0%
0
SC 13G/A
Feb 04, 2022
wellington management group llp
8.34%
38,655,904
SC 13G
Feb 16, 2021
ra capital management, l.p.
9.99%
41,543,004
SC 13G
Feb 05, 2021
novo holdings a/s
3.1%
12,893,250
SC 13G/A
Oct 05, 2020
novo holdings a/s
5.4%
22,639,667
SC 13D/A
Aug 03, 2020
growth equity opportunities fund iv, llc
10.2%
42,638,131
SC 13D/A
Jul 31, 2020
abingworth llp
5.1%
21,064,222
SC 13D/A

VRNA Fair Value

Recent SEC filings of Verona Pharma

View All Filings
Date Filed Form Type Document
Dec 27, 2022
4
Insider Trading
Dec 27, 2022
4
Insider Trading
Dec 27, 2022
4
Insider Trading
Dec 27, 2022
SC 13D/A
13D - Major Acquisition
Dec 21, 2022
4
Insider Trading
Dec 21, 2022
4
Insider Trading
Dec 20, 2022
8-K
Current Report
Nov 15, 2022
S-8
Employee Benefits Plan
Nov 09, 2022
10-Q
Quarterly Report
Nov 09, 2022
8-K
Current Report

Latest Insider Trading transactions for VRNA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-12-23
ORBIMED ADVISORS LLC
sold
-49,576,600
22.8425
-2,170,370
-
2022-12-23
Gupta Rishi
sold
-49,576,600
22.8425
-2,170,370
-
2022-12-22
Poll Claire
sold
-646,032
2.6918
-240,000
general counsel
2022-12-22
ORBIMED ADVISORS LLC
sold
-86,424,200
21.7721
-3,969,500
-
2022-12-22
Gupta Rishi
sold
-86,424,200
21.7721
-3,969,500
-
2022-12-20
Hahn Mark W
sold
-1,269,060
2.1151
-600,000
chief financial officer
2022-12-20
ZACCARDELLI DAVID
sold
-1,269,600
2.116
-600,000
president and ceo
2022-11-22
Poll Claire
gifted
-
-
170,000
general counsel
2022-11-22
Poll Claire
gifted
-
-
-170,000
general counsel
2022-11-01
Hahn Mark W
sold
-22,011.4
1.6726
-13,160
chief financial officer

1–10 of 50

About Verona Pharma

David S. Zaccardelli
30
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

VRNA Income Statement

2022-09-30
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenue$ 0$ 40,000$ 0$ 40,000
Gross profit040,000040,000
Operating expenses    
Research and development9,83822,56042,44556,697
Selling, general and administrative5,29010,88318,25628,150
Total operating expenses15,12833,44360,70184,847
Operating (loss)/profit(15,128)6,557(60,701)(44,847)
Other (expense)/income    
Research and development tax credit2,1274,7498,83810,655
Interest income779495911
Interest expense(116)(86)(291)(255)
Fair value movement on warrants04002,244
Foreign exchange (loss)/gain(3,245)(86)(6,830)117
Total other (expense)/income, net(455)4,6212,67612,772
(Loss)/profit before income taxes(15,583)11,178(58,025)(32,075)
Income tax expense(64)(127)(225)(232)
Net (loss)/profit$ (15,647)$ 11,051$ (58,250)$ (32,307)
Profit/(loss) per share, basic (in dollars per share)$ (0.03)$ 0.02$ (0.12)$ (0.07)
Profit/(loss) per share, diluted (in dollars per share)$ (0.03)$ 0.02$ (0.12)$ (0.07)
Weighted-average shares outstanding, basic (in shares)544,134,136475,334,354503,751,844471,159,171
Weighted-average shares outstanding, diluted (in shares)544,134,136515,819,439503,751,844471,159,171

VRNA Balance Sheet

2022-09-30
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 231,701$ 148,380
Prepaid expenses3,3554,037
Tax and tax incentive receivable20,32115,583
Other current assets3,0772,063
Total current assets258,454170,063
Non-current assets:  
Furniture and equipment, net8180
Goodwill544545
Equity interest15,00015,000
Right-of-use assets793899
Total non-current assets16,41816,524
Total assets274,872186,587
Current liabilities:  
Accounts payable8,00210,044
Accrued expenses22,97822,256
Operating lease liability569648
Taxes payable285147
Other current liabilities294327
Total current liabilities32,12833,422
Non-current liabilities:  
Term loan5,0354,874
Operating lease liability224286
Total non-current liabilities5,2595,160
Total liabilities37,38738,582
Commitments and contingencies
Shareholders' equity:  
Ordinary £0.05 par value shares; 608,138,246 and 489,177,550 issued, and 602,215,606 and 480,082,966 outstanding, at September 30, 2022 and December 31, 2021, respectively39,11931,855
Additional paid-in capital525,858385,070
Ordinary shares held in treasury(449)(603)
Accumulated other comprehensive loss(4,601)(4,601)
Accumulated deficit(322,442)(263,716)
Total shareholders' equity237,485148,005
Total liabilities and shareholders' equity$ 274,872$ 186,587